ASCO

ASCO 2018 Congress

English

Mandarin

Japanese

 

Expert interviews at ASCO 2018

 

Edward Kim talks about the relevance of biomarkers in choosing patients for immunotherapy and the usefulness/pitfalls of liquid biopsies.

Barbara Melosky talks about ongoing trials that evaluate afatinib/pembrolizumab combination therapy of squamous-cell carcinoma and potential combinations of anti-EGFR agents with anti-angiogenesis drugs.

Terufumi Kato talks about the nationwide screening project LC-SCRUM-Japan and the insights that have been obtained through these data in general and regarding squamous-cell lung cancer in particular.

 


ASCO 2017

Expert interviews at ASCO

 

Richard Baird on clinical trial data for treatment of cerebral metastases, including the Cambridge brain mets trial 1 (CamBMT1) phase 1B trial data that he presented at ASCO.

Anna Nowak on malignant mesothelioma: risk factors, prognostic markers, and clinical trial data for mesothelioma treatments to come out of the congress.

Yi-Long Wu, president of the Chinese Society of Clinical Oncology, discusses his society’s collaboration with memo – inOncology, and the approval of afatinib for EGFR+ NSCLC in China.

Maya Gottfried on NSCLC screening and treatment options

 


ASCO 2016

English

Spanish

Mandarin

 


ASCO 2015